# Safety and Immunogenicity of SYS6017 in Healthy Participants Aged 40 Years or More

> **NCT06954818** · PHASE1 · NOT_YET_RECRUITING · sponsor: **CSPC Megalith Biopharmaceutical Co.,Ltd.** · enrollment: 200 (estimated)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** A zoster mRNA vaccine SYS6017
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06954818
- **Lead sponsor:** CSPC Megalith Biopharmaceutical Co.,Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-10
- **Primary completion:** 2025-12-10
- **Final completion:** 2026-11-10
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06954818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06954818, "Safety and Immunogenicity of SYS6017 in Healthy Participants Aged 40 Years or More". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06954818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*